Clinical trials: Recurrent Hepatocellular Cancer
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC.
- Trial name
- NCT03563170
- Testing
- ETBX-011, GI-4000, haNK for infusion
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Liver Cancer
National Registry and Blood Bank of Patients With Liver Cancer
RATIONALE: Gathering health information about patients with liver cancer over time may help doctors learn more about the disease and may help the study of cancer in the future.
- Trial name
- NCT00482365
- Testing
- biologic sample preservation procedure, medical chart review, Patient interview
- Where
- 3 sites in United States
- Volunteers
- 151 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hepatocellular Carcinoma
P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
The main purpose of this trial is to evaluate the safety of the new adjuvant treatment of curative HCC, or the treatment of long-acting interferon P1101 alone, or the use of long-acting interferon P1101 and subsequent treatment…
- Trial name
- NCT04233840
- Testing
- P1101 (Ropeginterferon alfa-2b), Nivolumab
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- National Taiwan University Hospital
Liver Cancer
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00335829
- Testing
- bevacizumab, chemotherapy, embolization therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Yale University
Hepato Cellular Carcinoma (HCC)
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
This study will evaluate the efficacy and safety of therapy perioperative treatment with HAIC combined with donafenib and sintilimab (group A)/ donafenib combined with sintilimab (group B) compared with direct surgery (group C)…
- Trial name
- NCT06812039
- Testing
- HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery
- Where
- 3 sites in China
- Volunteers
- 165 people
- Sponsor
- Fudan University
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Solid Tumor, Non-Small Cell Lung Cancer Recurrent
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer Recurrent, Hepatocellular Carcinoma Recurrent
- Trial name
- NCT02423343
- Testing
- Galunisertib, Nivolumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
HCC, Adjuvant Therapy
Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC positive patients have a higher rate of postoperative recurrence.
- Conditions
- HCC, Adjuvant Therapy, Immunotherapy, Recurrence
- Trial name
- NCT06461936
- Testing
- Sintilimab, Lenvatinib
- Where
- China
- Volunteers
- 620 people
- Sponsor
- Chen Xiaoping
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Carcinoma, Hepatocellular
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
The primary purpose of the study is to explore whether treatment with PF-03446962 and best supportive care is better than placebo plus best supportive care in prolonging survival of patients affected by recurrent liver cancer.
- Trial name
- NCT01911273
- Testing
- PF-03446962, Best Supportive Care
- Where
- 4 sites in United States, Japan
- Volunteers
- 3 people
- Sponsor
- Pfizer
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue in patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01194206
- Testing
- stereotactic body radiation therapy
- Sponsor
- Case Comprehensive Cancer Center
Hepatocellular Carcinoma, Surgery
TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC.
- Conditions
- Hepatocellular Carcinoma, Surgery, Ablation
- Trial name
- TACE-RFA (NCT01833286)
- Testing
- TACE+RFA, re-resection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Resectable Hepatocellular Carcinoma
Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is a prospective, Two-arm, randomized，phase II clinical study of Sintilimab Combined With Lenvatinib Versus HAIC for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.
- Trial name
- NCT05519410
- Testing
- Sintilimab and Lenvatinib, HAIC-FOLFOX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
This phase II trial is studying how well giving bevacizumab together with erlotinib works in treating patients with advanced liver cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00365391
- Testing
- bevacizumab, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Liver Transplantation, Adjuvant FOLFOX Plus Lenvatinib
Stratification for F-L Therapy After LT
Objective: To stratify recipients who underwent adjuvant FOLFOX plus lenvatinib (F-L) therapy following liver transplantation (LT) for hepatocellular carcinoma and provide guidance for clinical adjuvant therapy.
- Conditions
- Liver Transplantation, Adjuvant FOLFOX Plus Lenvatinib, Machine Learning
- Trial name
- NCT06564103
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Xiao Xu
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Liver Cancer
Detect and Expunge Concealed Tumors of the Liver
The investigators long-term goal is to identify molecular and immunological signatures that can be used as biomarkers to accurately predict early recurrence and inform immunotherapeutic strategies in patients with hepatocellular…
- Trial name
- DTECT-Liver (NCT06141564)
- Where
- Vietnam
- Volunteers
- 360 people
- Sponsor
- Johns Hopkins University
Liver Cancer
Vaccine Therapy in Treating Patients With Liver Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have liver cancer.
- Trial name
- NCT00005629
- Testing
- AFP gene hepatocellular carcinoma vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Jonsson Comprehensive Cancer Center